Disease control and tumour shrinkage observed in CHM CDH17
Filed with ASX · · 3 pages · English
Sydney, Australia, 29 September 2025: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce it has achieved further disease control and tumour shrinkage in its CHM CDH17 Phase 1/2 clinical trial, as the Safety Monitoring Committee (SMC) for the trial declares Dose Level 2 is safe for additional exploration. The encouraging early
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Appendix 4E and Annual Report
- CHM CDH17 Clinical Trial Update
- Chimeric receives $2.5 M advance on FY25 R&D tax incentive
- CHM CDH17 receives FDA Fast Track
- CHM CDH17 advances to Dose Level 2
Later from Chimeric Therapeutics
- Additional complete responses in CHM CORE-NK Phase 1b trial
- Response to ASX Query Letter
- Pause in Trading
- CHM CORE NK Combination Phase 1b trial update
- 75% disease control observed in CHM CDH17 trial
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics